Prescribing trends for anti-asthma drugs in Tasmania following the National Asthma Campaign

Journal of Clinical Pharmacy and Therapeutics

Volumn 21, Issue 5, 1996, Pages 317-324

  Jacobson, G A ^a   Peterson, G M ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; IPRATROPIUM BROMIDE; THEOPHYLLINE;

ARTICLE; ASTHMA; AUSTRALIA; DISEASE MANAGEMENT; HUMAN; INHALATIONAL DRUG ADMINISTRATION; PHARMACY; PRESCRIPTION;

EID: 0030444230     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.1996.tb00025.x     Document Type: Article

References (35)

1. Weiss KB, Wagener DK. (1990) Changing patterns of asthma mortality: identifying target populations at risk. Journal of the American Medical Association, 264, 1683-1687.
2. Jackson R, Sears MR, Beaglehole R, Rea HH. (1988) International trends in asthma mortality: 1970-1985. Chest, 94, 914-918.
3. National Health and Medical Research Council. (1988) Asthma in Australia. Strategies for reducing morbidity and mortality. Australian Government Publishing Service, Canberra.
4. Keating G, Mitchell EA, Jackson R, Beaglehole R, Rea H. (1984) Trends in sales of drugs for asthma in New Zealand, Australia, and the United Kingdom, 1975-81. British Medical Journal, 289, 348-351.
5. Klaukka T, Peura S, Martikainen J. (1991) Why has the utilisation of antiasthmatics increased in Finland? Journal of Clinical Epidemiology, 44, 859-863.
6. Hay IFC, Higenbottam TW. (1987) Has the management of asthma improved? Lancet, 2, 609-611.
7. Woolcock AJ. (1986) Worldwide differences in asthma prevalence and mortality. Why is asthma mortality so low in the USA? Chest, 90 (Suppl.), 40-45.
8. Jenkins MA, Hurley SF, Jolley DJ, Oliver RJ, McLean AJ, McNeil JJ. (1988) Trends in Australian mortality of asthma 1979-1985. Medical Journal of Australia, 149, 620-624.
9. Wilson JW, Jenkins CR. (1996) Asthma mortality: where is it going? [Editorial]. Medical Journal of Australia, 164, 391-392.
10. National Asthma Campaign. (1992) Report on the cost of asthma in Australia. National Asthma Campaign, Melbourne.
11. Editorial. (1992) International consensus report urges sweeping reform in asthma treatment. Journal of the American Medical Association, 267, 2153-2154.
12. National Heart, Lung, Blood Institute. (1992) International consensus report on diagnosis and management of asthma. US Department of Health and Human Services, Bethesda, MD.
13. Woolcock A, Rubinfeld AR, Scale JP, et al. (1989) Asthma management plan, 1989. Medical Journal of Australia, 151, 650-653.
14. Tse M, Bridges-Webb C. (1993) Asthma management in general practice. Medical Journal of Australia, 158, 766-770.
15. Breslin ABX. (1993) New developments in anti-asthma drugs. Medical Journal of Australia, 158, 779-782.
16. Spitzer WO, Suissa S, Ernst P, et al. (1992) The use of beta-agonists and the risk of death and near death from asthma. New England Journal of Medicine, 326, 501-506.
17. Sears MR, Taylor RB, Print CG, et al. (1990) Regular inhaled beta-agonist treatment in bronchial asthma. Lancet, 336, 1391-1396.
18. Grainger J, Woodman K, Pearce N, et al. (1991) Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax, 46, 105-111.
19. Crane J, Pearce N, Flatt A, et al. (1989) Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet, 1, 917-922.
20. van Schayck CP, Dompeling E, van Herwaarden CLA, et al. (1991) Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. British Medical Journal, 303, 1426-1431.
21. Ernst P, Spitzer WO, Suissa S, et al. (1992) Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. Journal of the American Medical Association, 268, 3462-3464.
22. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. (1994) Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. Journal of the American Medical Association, 271, 1412-1416.
23. Chapman KR, Kesten S, Szalai JP. (1994) Regular vs. as-needed inhaled salbutamol in asthma control. Lancet, 343, 1379-1382.
24. 2-agonists in asthma: much ado about nothing? Still cause for concern. British Medical Journal, 309, 794-795.
25. Jacobson GA, Friesen WT, Peterson GM, Rumble RH, Polack AE. (1992) Psychoactive drug prescribing in the Tasmanian community. Medical Journal of Australia, 157, 20-24.
26. Peterson GM, Sugden JE. (1995) Educational program to improve the dosage prescribing of allopurinol. Medical Journal of Australia, 162, 74-77.
27. WHO Collaborating Centre for Drug Statistics Methodology. (1993) Anatomical therapeutic chemical (ATC) classification index including defined daily doses (DDDs) for plain substances. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway.
28. The Pharmacy Guild of Australia. (1994) 1994 Guild Digest. Fyshwick, ACT: Paragon Printers.
29. Jenkins MA, Hurley SF, Bowes G, McNeil JJ. (1990) Use of antiasthmatic drugs in Australia. Medical Journal of Australia, 153, 323-328.
30. National Health Survey 1989-90. (1991) Asthma and other respiratory conditions, Australia. Australian Bureau of Statistics, Canberra. Catalogue no. 4373.0.
31. Kamada AK. (1994) Therapeutic controversies in the treatment of asthma. Annals of Pharmacotherapy, 28, 904-914.
32. Barnes PJ. (1995) Inhaled glucocorticoids for asthma. New England Journal of Medicine, 332, 868-875.
33. Johnston IDA. (1990) Theophylline in the management of airflow obstruction. Difficult drug to use, few clinical indications. British Medical Journal, 300, 929-931.
34. Phin S, Oates RK. (1993) Variations in the treatment of childhood asthma. Medical Journal of Australia, 159, 662-666.
35. Phelan PD. (1995) Childhood asthma. The role of corticosteroids. Current Therapeutics, 36 (7), 57-63.